M&A / Deals Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers BioPharma DiveEquipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.M&A / DealsImmunology & InflammationRead full story pharminent April 15, 2026 (Last updated: April 16, 2026) BioPharma Dive Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases. M&A / DealsImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Travere wins long-awaited approval for kidney disease drugNext: Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
